AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01747850 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spray
Description: Study subjects will gradually increase the maximal allowed dose of Placebo starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The Placebo treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Placebo Spray that will be decreased by 50%). Then exposure to Placebo will be stopped (so there will be a total of 12 weeks Placebo treatment exposure).
Study NCT01095510 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE
Study NCT03995693 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measure of central and cutaneous temperatures
Description: Wireless sensors will be placed on the skin of the arm, chest, back, abdomen, thigh and calf using adhesive tape. A wireless thermometric pill will be ingested the morning of the experiment. These will allow the measurement of skin and central temperatures throughout the exercise protocol.
Study NCT03995693 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Measure of perceived exertion, pain perception and affective response
Description: 100 points scales (CR100) will be used to measure perceived exertion and pain perception immediately before ingesting the gas sampling. At the same time, affective responses will be assessed using the Feeling scale.
Study NCT03995693 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Measure of sweat and urine production
Description: Sweat production and sampling will be performed by measuring body weight before and after exercise, after voiding the bladder. Mass loss through the urine and gases will be accounted for in order to compute sweat production. A sweat sample will be collected using a cotton gauze placed into a plastic collector affixed in the upper back of the participants. A urine sample will be taken from the urine collected at the end of the exercise period. Urine and sweat volumes along with respective urea concentrations will be used to compute protein oxidation during exercise.
Study NCT02439073 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation
Description: The postoperative intervention are the same in both intervention groups and consists of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.The postoperative physical exercise consists of an individually prepared supervised strength exercise - and a group-based cardiovascular exercise twice a week (60 minutes/session) on non-consecutive days for 12 weeks, a total of 24 sessions.
Study NCT02439073 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: The postoperative intervention are the same in both intervention groups and consists of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.The postoperative physical exercise consists of an individually prepared supervised strength exercise - and a group-based cardiovascular exercise twice a week (60 minutes/session) on non-consecutive days for 12 weeks, a total of 24 sessions.
Study NCT05101031 — intervention group
Intervention type: DEVICE
Intervention: Starling SV
Description: The Starling SV will monitor the change in hemodynamic variables (i.e. CO, SV, HR, SV) as assessed during the initial fluid resuscitation in individuals with hypotension related to infection.
Study NCT02290730 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape
Description: Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the lower trapezius in a stretched position. The tape can be divided into one, two or three tails to cover the whole muscle from origin to insertion
Study NCT02798250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
Study NCT02798250 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dexcom G4 Platinum glucose sensor
Study NCT02798250 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Accu Chek Combo insulin pump
Study NCT00963391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ABHS use
Description: Centers assigned to the intervention group were provided with ABHS dispensers with a gel solution with ethyl alcohol at 62% as active ingredient (Purell®, GOJO Industries, Dayton, Ohio). A total of 85 dispensers were installed, one dispenser was installed in each center of size less than 14 children, and one per classroom plus an additional one for common areas in centers with more than 28 children. Proper safety measures were followed.~Standardized ABHS training workshops for staff and children in centers allocated to the intervention were carried out simultaneously with dispenser installation. Thirty minute refresher sessions about ABHS technique were provided to staff and children on a monthly basis, for a total of 8 sessions per center.
Study NCT00732212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Doppler endoscopic ultrasound probe for blood flow detection
Description: Used for blood flow detection
Study NCT00732212 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard endoscopic hemostasis
Description: Per current treatment guidelines for non-variceal UGI lesions - based upon stigmata of hemorrhage \& visual cues for risk stratification and completion of endoscopic treatment.
Study NCT00869752 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-IGF-1R recombinant monoclonal antibody MK-0646
Description: MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
Study NCT00869752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
Study NCT00869752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
Study NCT01592071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Replace reactive foods with non-reactive foods
Description: Subjects were provided with the test results and an individualized dietary plan based on replacing reactive foods with non-reactive foods as replacements per the Immuno Bloodprint results.
Study NCT01698385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet and exercise counseling
Description: diet and exercise counseling, setting of specific goals, follow-up of achievements, laboratory tests and measurements
Study NCT01027715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EEG monitoring and treatment of EEG seizures
Description: Seizures will prompt treatment with loading doses of phenobarbital (20mg/kg), fosphenytoin (20mg/kg),and midazolam (0.05mg/kg bolus and .15mg/kg/hr infusion tapered over 48 hours)in that order for persisting seizures.
Study NCT00485017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THR-4109
Description: THR-4109 maximum dose in study is 115 mg via oral capsule daily in a.m. and 115 mg via oral capsule daily in p.m. for 24 weeks
Study NCT00485017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules daily in a.m. and in p.m. for 24 weeks
Study NCT02899936 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 drug dose - IDA
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
Study NCT02899936 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 drug dose - DA
Description: Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA)
Study NCT01917747 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigator
Description: The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed. In the second part of the study, further educational tools are given to parent(s) and discussion of additional follow up mechanisms, including community hearing services and types of interventions for pediatric hearing loss is imparted.
Study NCT01917747 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard scheduling and follow-up
Description: The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test, as is standard practice.
Study NCT01217944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: 0.5 mg ranibizumab intravitreal injection
Study NCT01217944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: 0.5 mg ranibizumab intravitreal injection
Study NCT01217944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin PDT
Description: Verteporfin (6 mg/m2) intravenous infusion
Study NCT01217944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham Ranibizumab
Description: Empty vial to mimic the intravitreal injection
Study NCT01217944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham Ranibizumab
Description: Empty vial to mimic the intravitreal injection
Study NCT01217944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sham verteporfin PDT
Description: Sham vPDT intravenous infusion of dextrose 5% solution followed by light application (PDT).
Study NCT01217944 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham verteporfin PDT
Description: Sham vPDT intravenous infusion of dextrose 5% solution followed by light application (PDT).
Study NCT04670341 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chewing tapioca pearls in bubble tea drinks
Description: Saliva was collected on the first day before bubble tea consumption (pretest) and on the third day after bubble tea consumption (posttest); collection was conducted in the morning (09:00 a.m.-12.00 p.m.).
Study NCT04670341 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: drink tea without chewing tapioca pearls
Description: Saliva was collected on the first day before drink tea without tapioca pearl (pretest) and on the third day after tea consumption (posttest); collection was conducted in the morning (09:00 a.m.-12.00 p.m.).
Study NCT04064593 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polygraphy
Description: The polygraphy consists of recording during sleep, respiratory flow by mean of a nasal cannula, respiratory movement by mean of a thoracic belt with inductance plethysmography, blood oxygenation and heartbeats by a fingertip transcutaneous oxymetry.~Starting and ending of the recording will be programmed based on patient interview regarding usual sleep hours.~Polygraphy data are anonymized before being sent to the Cloud and therefore to the core lab.~Polygraphic data will be scored in centralized manner.~Results of the polygraphy will be sent to the cardiology department with advice for treatment and follow-up.~If necessary, the core-lab will provide tele-counseling regarding SDB management.
Study NCT02433340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-122
Study NCT03218384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose
Description: Intravenous Ferric Carboxymaltose 750 mg mixed under sterile conditions in 100 ml of normal saline for final concentration of 7.5 mg/ml and administered via volumetric infusion pump over 15 minutes.
Study NCT03218384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 100 ml of normal saline solution, and administered via volumetric infusion pump over 15 minutes.
Study NCT03218384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 31P MRS/MRI
Description: Each participant will perform the same rhythmic plantar extension exercise protocol twice, for sequential acquisition of magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI) measurements. For the exercise protocol, the participant will lay supine on the scanning table with the right leg inside the volume coil. The exercise consists of repeated plantar flexion movements using resistance bands at a frequency of one repetition per second for 1-2 minutes. Data are collected continuously for 2 minutes before the exercise (baseline), during exercise, and 5 minutes after the exercise for the MRS and MRI experiments.
Study NCT03218384 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 31P MRS/MRI
Description: Each participant will perform the same rhythmic plantar extension exercise protocol twice, for sequential acquisition of magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI) measurements. For the exercise protocol, the participant will lay supine on the scanning table with the right leg inside the volume coil. The exercise consists of repeated plantar flexion movements using resistance bands at a frequency of one repetition per second for 1-2 minutes. Data are collected continuously for 2 minutes before the exercise (baseline), during exercise, and 5 minutes after the exercise for the MRS and MRI experiments.
Study NCT02905266 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: -Specified dose on specified days
Study NCT02905266 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: -Specified dose on specified days
Study NCT00402168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: IV, IV Infusion, 5 mg/kg once every 28 days for one year
Study NCT00402168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A
Description: Tablets, Oral, Trough of 100-250 ng/mL, 2\* daily for one year
Study NCT00402168 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Tablets, Oral, Trough of 5-10 ng/mL, 2\* daily for one year
Study NCT01854359 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Idebenone
Study NCT01787461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Imedeen
Description: Two tablets per day for 6 months
Study NCT01787461 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two tablets per day for 6 months
Study NCT00311766 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymosin Beta 4
Description: Topical administration, 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days
Study NCT01871701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram
Study NCT01871701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetiapine
Study NCT01871701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Description: Moxifloxacin
Study NCT01871701 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00311766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical administration, 0.00% Thymosin Beta 4 gel qd up to 56 days
Study NCT03073421 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative interview
Description: This interview will be 2 hours in length and will be conducted with a Peer Research Assistant (PRA). The PRAs will be women living with HIV.
Study NCT02536898 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fracture Liaison Service
Study NCT02536898 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Current treatment
Study NCT03678701 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-meal 100% whey protein intake
Description: Participants in the protein group will be provided 100% whey protein powder and will be advised to drink 30g of protein dissolved in 237ml (8oz) of water, one hour before lunch and dinner.
Study NCT04868955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral screen training
Description: Oral screen training (IQoro®) during 13 weeks.
Study NCT01611038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Methylselenocysteine
Description: Methylselenocysteine capsule given daily
Study NCT01611038 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule given daily
Study NCT01687608 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AskBio009
Description: Single dose IV injection
Study NCT03568240 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Patients suffering from Sleep apnea
Description: PSG test
Study NCT01154868 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Alveolar ridge augmentation
Description: Under local anesthesia, full-thickness mucoperiosteal flaps will be elevated, followed by degranulation, and collection of all clinical measurements. Crestal and vertical releasing cuts will be performed using diamond-coated discs on the edentulous ridge in need of augmentation. A sequence of bone chisels and osteotomes will be used to split the alveolar ridge in half until a desirable width for implant placement is achieved. Healos® will then be inserted between both osseous plates. Fixation screws will be used as needed to stabilize the expanded alveolar ridge. Collagen barrier membranes (Ossix Plus) will be used to cover the osseous wound. Flaps will be approximated to achieve primary wound closure.
Study NCT03965013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC0268-0965
Description: 2 to 3 dose levels will be tested in Part 1. 3 to 5 dose levels will be tested in Part 2
Study NCT03965013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo given in Part 1
Study NCT03965013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Insulin glargine given at a fixed dose level of 0.5 U/kg
Study NCT03850860 — intervention group
Intervention type: OTHER
Intervention: empirical antibiotherapy
Description: comparison of the outcome in the 2 groups having had 2 different empirical antibiotherapies
Study NCT00700440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C225 (cetuximab)
Description: one week before and then weekly during radiotherapy
Study NCT03087513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex Injection [Bridion]
Description: The study participants will receive 10 ml syringe containing Sugammadex (2mg/kg) in the first phase followed by Placebo 10 ml syringe containing of 0.9% of normal saline in the second phase.
Study NCT03087513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The study participants will receive Placebo 10 ml syringe containing of 0.9% of normal saline in the first phase followed by 10 ml syringe containing Sugammadex (2mg/kg) in the second phase.
Study NCT00720590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atazanavir
Description: 400 mg of atazanavir (two 200-mg capsules) per day for 4 weeks
Study NCT00720590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir
Description: 400 mg/100 mg of lopinavir/ritonavir (three soft-gel capsules, each containing 133.3 mg lopinavir and 33.3 mg ritonavir) twice per day with food for 4 weeks
Study NCT00720590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Daily dose of placebo for 4 weeks
Study NCT00720590 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily dose of placebo for 4 weeks
Study NCT00795704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mulberry Leaf Extract
Description: Mulberry Leaf Extract 1000 mg by mouth three times daily for 3 months
Study NCT01001559 — intervention group
Intervention type: DRUG
Intervention: L-methylfolate
Description: Subjects must have been on their respective therapies for a minimum of 60 days. L-methylfolate dosing was 7.5 mg or 15 mg daily
Study NCT01001559 — intervention group
Intervention type: DRUG
Intervention: Selective serotonin reuptake inhibitor (SSRI)
Description: Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.